Global Information
회사소개 | 문의

원발성 전신성 유전분증 : 세계 임상시험 리뷰

Primary Systemic Amyloidosis Global Clinical Trials Review, H1, 2016

리서치사 GlobalData
발행일 2016년 06월 상품 코드 305094
페이지 정보 영문 62 Pages
가격
US $ 2,500 ₩ 2,803,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,606,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 8,409,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


원발성 전신성 유전분증 : 세계 임상시험 리뷰 Primary Systemic Amyloidosis Global Clinical Trials Review, H1, 2016
발행일: 2016년 06월 페이지 정보 : 영문 62 Pages

한글목차

원발성 전신성 유전분증(Primary Systemic Amyloidosis)에 관한 임상 연구의 최신 동향에 대해 분석했으며, 질환 및 치료법 개요, 주요 선진국가 및 신흥국가의 임상시험 상황, 지역·단계(상)·단계별 진행 상황, 유망한 스폰서, 각 기업 및 연구기관에서의 연구 진행 상황, 유망한 치료제 등의 정보를 전해드립니다.

1. 서론

  • 원발성 전신성 유전분증
  • 본 보고서 개요

2. 각 지역에서의 임상시험 상황

  • 각국의 임상시험 건수와 평균 피험자수
    • 아시아태평양 지역 주요 국가
    • 유럽 주요 5개국
    • 북미 주요 국가

3. G7 국가에서의 임상시험 건수 : 대사성 질환 임상시험 전체 대비 원발성 전신성 유전분증 임상시험 비율

4. G7 국가에서의 임상시험 건수 : 단계(상)별

5. G7 국가에서의 임상시험 건수 : 진척 상황별

6. E7 국가에서의 임상시험 건수 : 대사성 질환 임상시험 전체 대비 원발성 전신성 유전분증 임상시험 비율

7. E7 국가에서의 임상시험 건수 : 진척 상황별

8. 단계(상)별 임상시험 건수

  • 진행중인 임상시험 : 단계별

9. 진척 상황별 임상시험 건수

10. 일정기간에 채용된 피험자

11. 스폰서 종류별 임상시험 건수

12. 유망한 스폰서

  • 원발성 전신성 유전분증 치료제 임상시험에 참여하고 있는 주요 기업

13. 유망한 치료제

14. 임상시험 프로파일

  • 대표적 기업의 임상시험 개요
    • Prothena Corporation plc
    • Onclave Therapeutics Limited
  • 대표적 연구기관 및 병원의 임상시험 개요
    • National Cancer Institute
    • Boston Medical Center
    • Mayo Clinic
    • The University of Texas M. D. Anderson Cancer Center
    • Eastern Cooperative Oncology Group
    • Nanjing University
    • Fred Hutchinson Cancer Research Center
    • The Cleveland Clinic
    • University Hospital, Limoges
    • Children's Oncology Group

15. 대표적 임상시험 5건 개요

부록

도표

LSH 14.06.12

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

영문목차

GlobalData's clinical trial report, "Primary Systemic Amyloidosis Global Clinical Trials Review, H1, 2016" provides an overview of Primary Systemic Amyloidosis clinical trials scenario. This report provides top line data relating to the clinical trials on Primary Systemic Amyloidosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
  • Clinical Trials by G7 Countries: Proportion of Primary Systemic Amyloidosis to Metabolic Disorders Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Primary Systemic Amyloidosis to Metabolic Disorders Clinical Trials
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Primary Systemic Amyloidosis Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials by Region, 2016*
  • Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2016*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, North America, Top Countries, 2016*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016*
  • Proportion of Primary Systemic Amyloidosis to Metabolic Disorders Clinical Trials, G7 Countries (%), 2016*
  • Primary Systemic Amyloidosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Primary Systemic Amyloidosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Primary Systemic Amyloidosis to Metabolic Disorders Clinical Trials, E7 Countries (%), 2016*
  • Primary Systemic Amyloidosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials by Phase, 2016*
  • Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials In Progress by Phase 2016*
  • Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Primary Systemic Amyloidosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

List of Figures

  • Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials by Region (%), 2016*
  • Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2016*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, North America, Top Countries (%), 2016*
  • Proportion of Primary Systemic Amyloidosis to Metabolic Disorders Clinical Trials, G7 Countries (%), 2016*
  • Primary Systemic Amyloidosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Primary Systemic Amyloidosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Primary Systemic Amyloidosis to Metabolic Disorders Clinical Trials, E7 Countries (%), 2016*
  • Primary Systemic Amyloidosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials by Phase (%), 2016*
  • Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2016*
  • Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Primary Systemic Amyloidosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
  • GlobalData Methodology
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
La Merie Publishing
BCC Research